Medeon

SEQ_NO	1	Date of announcement	2025/10/17	Time of announcement	16:03:25
Subject	The Company has been required by TPEx to announce the financial data according to the regulations.
Date of events	2025/10/15	To which item it meets	paragraph 53
Statement	1.Date of occurrence of the event: 2025/10/15 2.Cause of occurrence:Announced as required by the TPEx 3.Financial and business information: Unit: (NT$million) (1) Monthly Sep 2025 Sep 2024 YoY Change % ————————————————————————— Sales revenue 37.760 23.838 58.40% Loss before income tax (70.962) (81.925) 13.38% Net Loss attributable to Owners of the parent (66.936) (76.322) 12.30% EPS (NT$) (0.73) (0.83) 12.30% (Losses reduced) =========================================================================== (2)Quarterly Q2 2025 Q2 2024 YoY Change % ————————————————————————— Sales revenue 110.382 63.526 73.76% Loss before income tax (188.238) (216.085) 12.89% Net Loss attributable to Owners of the parent (178.160) (212.458) 16.14% EPS (NT$) (1.93) (2.31) 16.45% (Losses reduced) =========================================================================== (3)Cumulative for the last four seasons Latest 4 quarters accumulation (Q3 2024 to Q2 2025) ————————————————————————— Revenue 394.401 Loss before income tax (806.853) Net Loss attributable to Owners of the parent (749,380) EPS (NT$) (8.12) =========================================================================== 4.Any material information that needs to be specified according to Article 4 of Taipei Exchange Procedures for Verification and Disclosure of Material Information of Companies with TPEx Listed Securities: Medeon has disclosed material information titled ‘Urocross Retrieval Sheath Receives FDA 510(k) Clearance as the First Approved Accessory to the Urocross Expander System’ in accordance with Article 53 over the past six business days. 5.Any material information in a press conference listed under Article 11 of Taipei Exchange Procedures for Verification and Disclosure of Material Information of Companies with TPEx Listed Securities: Medeon has not held any press conferences to explain material information in the past six business days. 6.Any other matters that need to be specified: (1)The aforementioned financial information for June 2025 and its YOY comparison consists in the consolidated reviewed amounts prepared by the Company adopting the IFRS, and has not been audited (reviewed) by CPA; it is only for reference by investors. (2)The information for the latest quarter (Q2 2025) refers to single quarter amounts, not cumulative amounts from the latest financial reports, and are consolidated amounts prepared under the IFRS, which have been audited (reviewed) by CPA; it is only for reference by investors. (3)The information accumulated over the last 4 quarters consists in the consolidated amounts from Q3 2024 to Q2 2025 prepared by the Company adopting the IFRS, and has been audited (reviewed) by CPA; it is only for reference by investors.